

**MARKSANS PHARMA LIMITED**

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2013

**PART 1**

(₹ in Lakhs)

Sr. No.	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Previous Year ended
		30.06.2013 (UNAUDITED)	31.03.2013 (AUDITED)	30.06.2012 (UNAUDITED)	31.03.2013 (AUDITED)
1	Income				
	a) Net Sales/ Income from Operations (Net of excise duty)	7,202.09	5,867.09	3,756.59	19,229.70
	b) Other Operating Income	270.38	(24.20)	66.68	417.18
	<b>Total Income from operations (net)</b>	<b>7,472.47</b>	<b>5,842.89</b>	<b>3,823.27</b>	<b>19,646.88</b>
2	Expenses				
	a) Cost of Material Consumed	2,463.49	1,129.63	1,468.94	6,595.75
	b) Purchase of Stock - in- trade	782.11	1,183.51	312.92	2,755.31
	c) Changes in Inventories of finished goods , work-in -progress and stock- in- trade	155.79	923.64	(2.49)	919.31
	d) Employee benefits expense	468.06	485.30	353.42	1,539.25
	e) Depreciation and amortisation expense	220.46	218.37	214.57	870.33
	f) Other expenses	1,442.02	(1,099.09)	3,205.39	2,993.19
	<b>Total Expenses</b>	<b>5,531.93</b>	<b>2,841.36</b>	<b>5,552.75</b>	<b>15,673.14</b>
3	<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>1,940.54</b>	<b>3,001.53</b>	<b>(1,729.48)</b>	<b>3,973.74</b>
4	Other Income	-	-	-	-
5	<b>Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)</b>	<b>1,940.54</b>	<b>3,001.53</b>	<b>(1,729.48)</b>	<b>3,973.74</b>
6	Finance cost	219.75	298.38	243.34	1,013.24
7	<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)</b>	<b>1,720.79</b>	<b>2,703.15</b>	<b>(1,972.82)</b>	<b>2,960.50</b>
8	Exceptional items	-	-	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7-8)</b>	<b>1,720.79</b>	<b>2,703.15</b>	<b>(1,972.82)</b>	<b>2,960.50</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	41.96	(997.77)	-	(997.77)
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>1,678.83</b>	<b>3,700.92</b>	<b>(1,972.82)</b>	<b>3,958.27</b>
12	Less: Extraordinary Item	-	-	-	-
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>1,678.83</b>	<b>3,700.92</b>	<b>(1,972.82)</b>	<b>3,958.27</b>
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,853.07	3,853.07	3,678.07	3,853.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year				5,794.56
16	a) Earnings Per Share (before extraordinary items.Rs.)- Basic	0.44	0.96	(0.54)	1.03
	Diluted	0.44	0.96	(0.51)	1.03
	b) Earnings Per Share(after extraordinary items- Rs.)- Basic	0.44	0.96	(0.54)	1.03
	Diluted	0.44	0.96	(0.51)	1.03
<b>PART 2</b>					
<b>A PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding:				
	- Number of Shares	187,999,472	188,634,244	189,824,114	188,634,244
	- Percentage of Holding	48.79%	48.96%	51.61%	48.96%
2	Promoters and Promoter group Shareholdings	197,307,732	196,672,960	177,983,090	196,672,960
	a). Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A
	b). Non-encumbered				
	- Number of Shares	197,307,732	196,672,960	177,983,090	196,672,960
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	51.21%	51.04%	48.39%	51.04%



B	INVESTOR COMPLAINTS	Quarter ended 30.06.2013
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.07.2013.
- 2 The Company has been de-registered from the purview of SICA and is no longer in BIFR.
- 3 The Company has published its consolidated financial statements separately. On consolidated basis, it has achieved revenue of ₹ 14,375.28 Lacs and PAT of ₹ 1,878.31 Lacs for the quarter ended 30.06.2013.
- 4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 5 The figure for the quarter ended March 31, 2013 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2013 and the unaudited published year to date figures up to December 31, 2012 being the date of the end of the third quarter of the preceding financial year.
- 6 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED

Place: Mumbai.  
Date: 29.07.2013



*[Handwritten Signature]*  
MARK SALDANHA  
Managing Director.

**MARKSANS PHARMA LIMITED**

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2013**

**PART 1**

(₹ in Lakhs)

Sr. No.	PARTICULARS	Quarter ended	Quarter ended	Quarter ended	Previous Year
		30.06.2013 (UNAUDITED)	31.03.2013 (AUDITED)	30.06.2012 (UNAUDITED)	31.03.2013 (AUDITED)
1	Income				
	a>. Net Sales/ Income from Operations (Net of excise duty)	14,103.11	12,390.02	9,464.22	43,842.24
	b>. Other Operating Income	272.17	(21.17)	72.10	439.54
	<b>Total Income from operations (net)</b>	<b>14,375.28</b>	<b>12,368.85</b>	<b>9,536.32</b>	<b>44,281.78</b>
2	Expenses				
	a) Cost of Material Consumed	4,313.89	2,695.37	3,020.45	13,592.88
	b) Purchase of Stock - in- trade	3,421.11	3,048.47	2,403.42	10,478.15
	c) Changes in Inventories of finished goods , work-in- progress and stock- in- trade	155.79	1,219.75	(2.49)	1,215.43
	d) Employee benefits expense	1,518.01	1,556.44	1,229.32	5,591.25
	e) Depreciation and amortisation expense	320.54	133.97	252.75	1,564.99
	f) Other expenses	2,320.77	(346.78)	3,911.36	6,024.71
	<b>Total Expenses</b>	<b>12,050.11</b>	<b>8,307.22</b>	<b>10,814.81</b>	<b>38,467.41</b>
3	Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)	2,325.17	4,061.63	(1,278.49)	5,814.37
4	Other Income	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	2,325.17	4,061.63	(1,278.49)	5,814.37
6	Finance cost	325.98	398.94	359.43	1,459.64
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	1,999.19	3,662.69	(1,637.92)	4,354.73
8	Exceptional items	-	-	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7-8)</b>	<b>1,999.19</b>	<b>3,662.69</b>	<b>(1,637.92)</b>	<b>4,354.73</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	82.78	(527.89)	-	(527.89)
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>1,916.41</b>	<b>4,190.58</b>	<b>(1,637.92)</b>	<b>4,882.62</b>
12	Less: Extraordinary Item	-	-	-	-
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>1,916.41</b>	<b>4,190.58</b>	<b>(1,637.92)</b>	<b>4,882.62</b>
14	Share of Profit/(Loss) of associates	-	-	-	-
15	Minority Interest	38.10	118.13	69.73	294.19
16	<b>Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)</b>	<b>1,878.31</b>	<b>4,072.45</b>	<b>(1,707.65)</b>	<b>4,588.43</b>
17	Paid up Equity Share Capital (Face Value Re.1 each)	3,853.07	3,853.07	3,678.07	3,853.07
18	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year				3,444.80
19	a) Earnings Per Share (before extraordinary items. Rs.)- Basic	0.50	1.09	(0.45)	1.27
	Diluted	0.50	1.09	(0.43)	1.27
	b) Earnings Per Share(after extraordinary items- Rs.)- Basic	0.49	1.06	(0.46)	1.19
	Diluted	0.49	1.06	(0.44)	1.19
<b>PART 2</b>					
<b>A PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding:				
	- Number of Shares	187,999,472	188,634,244	189,824,114	188,634,244
	- Percentage of Holding	48.79%	48.96%	51.61%	48.96%
2	Promoters and Promoter group Shareholdings	197,307,732	196,672,960	177,983,090	196,672,960
	a). Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of Holding	N.A	N.A	N.A	N.A
	(as a % of the total shareholding of Promoter and Promoter Group)				
	- Percentage of Holding	N.A	N.A	N.A	N.A
	(as a % of the total share capital of the Company)				
	b). Non-encumbered				
	- Number of Shares	197,307,732	196,672,960	177,983,090	196,672,960
	- Percentage of Holding	100%	100%	100%	100%
	(as a % of the total shareholding of Promoter and Promoter Group)				
	- Percentage of Holding	51.21%	51.04%	48.39%	51.04%
	(as a % of the total share capital of the Company)				



<b>B INVESTOR COMPLAINTS</b>		<b>Quarter ended 30.06.2013</b>
Pending at the beginning of the quarter		Nil
Received during the quarter		Nil
Disposed of during the quarter		-
Remaining unresolved at the end of the quarter		-

<b>PART 3 Standalone Information</b>	Quarter ended	Quarter ended	Quarter ended	Previous Year ended
	30.06.2013	31.03.2013	30.06.2012	31.03.2013
<b>PARTICULARS</b>	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(AUDITED)
Revenue	<b>7,472.47</b>	5,842.89	3,823.27	19,646.88
Profit Before Tax from Ordinary activities	<b>1,720.79</b>	2,703.15	(1,972.82)	2,960.50
Profit After Tax from Ordinary activities	<b>1,678.83</b>	3,700.92	(1,972.82)	3,958.27
Profit After Tax after extraordinary item	<b>1,678.83</b>	3,700.92	(1,972.82)	3,958.27

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29.07.2013.
- 2 The Company has been de-registered from the purview of SICA and is no longer in BIFR.
- 3 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 4 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 5 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 6 The figure for the quarter ended March 31,2013 are the balancing figures between audited figures in respect of the full financial year ended March 31,2013 and the unaudited published year to date figures up to December 31, 2012 being the date of the end of the third quarter of the preceeding financial year.
- 7 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED

Place: Mumbai.  
Date: 29.07.2013



*[Handwritten Signature]*  
MARK SALDANHA  
Managing Director.